Vir Biotechnology has partnered with Astellas Pharma to develop VIR-5500, its masked PSMA-targeting T-cell engager for ...

– Conference call scheduled for February 23, 2026, at 5:30 p.m. ET / 2:30 p.m. PT SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported ...

- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Researchers are increasingly using AI and biotechnology tools to better understand the ...

"We anticipate dosing the first patient in the combination dose expansion cohorts in both early-line MCRPC and metastatic hormone-sensitive prostate cancer over the coming months." (President, CEO & ...

Someone whose life is saved by a new medicine is unlikely to care whether it was invented at home or on the other side of the world. Yet America’s policymakers have begun treating China’s ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

Biotechnology has long relied on a handful of model microorganisms, such as Escherichia coli and Saccharomyces cerevisiae, whose genetics and physiology are ...

The iShares Global Healthcare ETF(NYSEMKT:IXJ) provides broad, established exposure to global healthcare giants, while the Invesco Nasdaq Biotechnology ETF(NASDAQ:IBBQ) offers a lower-cost ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

Explore advancements in biotechnology, from gene editing's ethical dilemmas to synthetic biology's commercial potential and ...